Alba Font-Tello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alba Font-Tello has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
58 shared publications - Xintao Qiu
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
55 shared publications - Agostina Nardone
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
53 shared publications - Avery Feit
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
53 shared publications - Cristina Guarducci
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
53 shared publications - Francisco Hermida-Prado
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
53 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S4. Schematic of flow cytometry experiments and differential impact of IFNg stimulation on HR+ breast cancer cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S4. Schematic of flow cytometry experiments and differential impact of IFNg stimulation on HR+ breast cancer cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S3. Summary of protein expression changes after 24 weeks of endocrine treatment (ET) and/or Palbociclib (palbo) treatment.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S3. Summary of protein expression changes after 24 weeks of endocrine treatment (ET) and/or Palbociclib (palbo) treatment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S8. Comprehensive analysis of fulvestrant and birinapant treatment in HR+ breast cancer cell.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S8. Comprehensive analysis of fulvestrant and birinapant treatment in HR+ breast cancer cell.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S5. Analysis of the impact of the ER axis on the response to IFNg stimulation in HR+ breast cancer cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S5. Analysis of the impact of the ER axis on the response to IFNg stimulation in HR+ breast cancer cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S1. Comprehensive analysis of protein expression data in immune and invasive cancer epithelial regions from in various patient cohorts.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S1. Comprehensive analysis of protein expression data in immune and invasive cancer epithelial regions from in various patient cohorts.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment